Chris Boshoff: Treatment Guidance for ALK+ Advanced NSCLC
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn about recent article Nancee Pronsati and colleagues authored:
“Advocates, patients, and medical experts have come together to help shape treatment guidance for people living with ALK+ advanced non-small cell lung cancer (NSCLC). The result of this work is an innovative article published in the journal Lung Cancer, which I hope will inspire important discussions about how to navigate cancer care.
The piece is authored in collaboration with ALK Positive Inc., people living with ALK+ advanced NSCLC, and healthcare professionals, and it provides patient-centered treatment guidance for people living with this aggressive form of lung cancer.
Congratulations to all involved in this important work, which bridges clinical research with real-world patient experience to help empower people living with NSCLC to take an informed and active role in their own care.”
Title: Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
Authors: Nancee Pronsati, Geoffrey Liu, Todd M. Bauer, Enriqueta Felip, Yasushi Goto, Gerald Green, Mary Grizzard, Michael Hamel, Julien Mazieres, Tony Mok, Stephanie Snow, Benjamin J. Solomon, Jan Stratmann, Ken Culver
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023